Everything below concerns albumin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
== Precautions == Protactinium is both toxic and highly radioactive; thus, it is handled exclusively in a sealed glove box. Its major isotope 231Pa has a specific activity of 0.048 curies (1.8 GBq) per gram and primarily emits alpha particles, which can be stopped by a thin layer of any material. However, it slowly decays into 227Ac, and then follows the more rapid actinium series, making its total activity (alpha, beta, and gamma) greater than one would calculate from that figure. As protactinium is present in small amounts in most natural products and materials, it is ingested with food or water and inhaled with air. Only about 0.05% of ingested protactinium is absorbed into the blood and the remainder is excreted. From the blood, about 40% of the protactinium deposits in the bones, about 15% goes to the liver, 2% to the kidneys, and the rest leaves the body. The biological half-life of protactinium is about 50 years in the bones, whereas its biological half-life in other organs has a fast and slow component. For example, 70% of the protactinium in the liver has a biological half-life of 10 days, and the remaining 30% for 60 days. The corresponding values for kidneys are 20% (10 days) and 80% (60 days). In each affected organ, protactinium promotes cancer via its radioactivity. The maximum amount of Pa allowed in the human body is 0.03 μCi (1.1 kBq), which corresponds to 0.5 micrograms of 231Pa. The maximum allowed concentrations of 231Pa in the air in Germany is 3×10−4 Bq/m3.
Certain serotonergic psychedelics and related non-hallucinogenic drugs, acting as serotonin 5-HT2A receptor agonists, have been reported to have mild stimulant and/or "psychic energizing" (i.e., acute antidepressant) effects, both in animals and humans. These effects are often present at low or sub-hallucinogenic doses. Psychedelics are also known to promote wakefulness or cause insomnia. Psychedelic and related drugs that have been reported to produce stimulant effects include the phenethylamines 2,5-DMA (DOH), DOM, DOET, DOPR, DON, MTFEM, Ariadne (4C-DOM; BL-3912; Dimoxamine), 2C-B, 2C-D, 2C-G-N, and ASR-2001 (2CB-5PrO), and the tryptamines 5-MeO-DiPT and 5-MeO-MiPT, among others. The lysergamide LSD has also been reported to have mild stimulant effects. Conversely, psilocybin does not seem to produce the same stimulant effects. The non-hallucinogenic Ariadne was under development as a potential pharmaceutical drug to take advantage of such effects in the treatment of conditions like depression in the 1970s, and reached phase 3 clinical trials for such indications, but was shelved reportedly for strategic economic reasons. ASR-2001, which is likewise non-hallucinogenic, is under development for use as a stimulant-like medication for treatment of psychiatric disorders. Serotonin 5-HT2A receptor agonists have been found to increase dopamine levels in brain areas like the frontal cortex, striatum, and nucleus accumbens in animal studies.
Ian Buruma, author and journalist; board member of Human Rights in China; fellow of European Council of Foreign Relations; journalist for The New York Review of Books and has written for The Guardian; held fellowships at Wissenschaftskolleg and at Woodrow Wilson International Center for Scholars in Washington, D.C.; was Alistair Horne fellow of St Antony's College in Oxford. Stephen Bush; ( b. 1990) columnist and associate editor at the Financial Times; has written for The Guardian, The Daily Telegraph, The Jewish Chronicle, Jewish News, Times of Israel, The i Paper and New Statesman; runner-up in the Young Journalist of the Year awards category in Press Awards; was awarded Political Studies Association's Journalist of the Year award;was appointed to chair the Board of Deputies of British Jews' Commission on Racial Inclusivity in the Jewish Community. Barbara Charone author of authorised biography of Keith Richards; board member of Chelsea F.C.; journalist and music critic for the NME, Rolling Stone, Sounds magazine and Creem; public relations and press director at WEA; founded the agency MBC PR where clients include Madonna, Depeche Mode, Primal Scream, Robert Plant, Pearl Jam, Rod Stewart and Christina Aguilera as well as comedians David Walliams, Graham Norton and Russell Brand; won the Music Week Press Award in 2006 and 2009; The Guardian included her on list of "The 20 most powerful celebrity makers" as "Britain's most powerful music PR", citing her reviving of careers of Madonna and Neil Diamond and establishing Duffy and Mark Ronson. Charone is on Chelsea F.C.
Sources: en.wikipedia.org
== Use during the 20th century == During the 20th century its use declined as governments regulated its ingredients (opium is a controlled substance in many countries). Beginning in late 2011, there was a period in which paregoric was not being manufactured in the United States. As of August 2012, however, the manufacture of paregoric had resumed.
== Medical uses == In the United States, daptomycin is indicated for use in adults for skin and skin structure infections caused by Gram-positive infections, S. aureus bacteremia, and right-sided S. aureus endocarditis. In 2017, the FDA extended daptomycin's indications to pediatric patients aged 1 to 17 years: labeling for complicated skin and skin structure infections in this population was approved on 29 March 2017, and labeling for S. aureus bacteremia in pediatric patients was approved on 1 September 2017. Daptomycin is not recommended for patients younger than one year of age, given the potential for adverse effects on the muscular, neuromuscular, and nervous systems observed in neonatal animal studies. It binds avidly to pulmonary surfactant, and so is generally ineffective in treating pneumonia.
=== Cardiac fibrosis and other fibroses === Some serotonergic agonist drugs cause fibrosis anywhere in the body, particularly the syndrome of retroperitoneal fibrosis, as well as cardiac valve fibrosis. In the past, three groups of serotonergic drugs have been epidemiologically linked with these syndromes. These are the serotonergic vasoconstrictive antimigraine drugs (ergotamine and methysergide), the serotonergic appetite suppressant drugs (fenfluramine, chlorphentermine, and aminorex), and certain anti-Parkinsonian dopaminergic agonists, which also stimulate serotonergic 5-HT2B receptors. These include pergolide and cabergoline, but not the more dopamine-specific lisuride. As with fenfluramine, some of these drugs have been withdrawn from the market after groups taking them showed a statistical increase of one or more of the side effects described. An example is pergolide. The drug was declining in use since it was reported in 2003 to be associated with cardiac fibrosis. Two independent studies published in The New England Journal of Medicine in January 2007 implicated pergolide, along with cabergoline, in causing valvular heart disease. As a result of this, the FDA removed pergolide from the United States market in March 2007. (Since cabergoline is not approved in the United States for Parkinson's Disease, but for hyperprolactinemia, the drug remains on the market. Treatment for hyperprolactinemia requires lower doses than that for Parkinson's Disease, diminishing the risk of valvular heart disease).
Acanthodrilidae Ailoscolecidae – the Pyrenees and the Southeastern United States Almidae – tropical equatorial (South America, Africa, Indo-Asia) Benhamiinae – Ethiopian, Neotropical (a possible subfamily of Octochaetidae) Criodrilidae – southwestern Palaearctic: Europe, Middle East, Russia and Siberia to Pacific coast; Japan (Biwadrilus); mainly aquatic Diplocardiinae – Gondwanan or Laurasian? (subfamily of Acanthodrilidae) Enchytraeidae – cosmopolitan but uncommon in tropics (usually classed with Microdriles) Eudrilidae – Tropical Africa south of the Sahara Exxidae – Neotropical: Central America and the Caribbean Glossoscolecidae – Neotropical: Central and South America, Caribbean Haplotaxidae – cosmopolitan distribution (usually classed with Microdriles) Hormogastridae – Mediterranean Kynotidae – Malagasian: Madagascar Lumbricidae – Holarctic: North America, Europe, Middle East, Central Asia to Japan Lutodrilidae – Louisiana, in the Southeastern United States Megascolecidae Microchaetidae – Terrestrial in Africa especially South African grasslands Moniligastridae – Oriental and Indian subregion Ocnerodrilidae – Neotropics, Africa; India Octochaetidae – Australasian, Indian, Oriental, Ethiopian, Neotropical Octochaetidae – Australasian, Indian, Oriental (subfamily if Benhamiinae is accepted) Sparganophilidae – Nearctic, Neotropical: North and Central America Tumakidae – Colombia, South America
Sources: en.wikipedia.org
==== World Health Organization ==== On January 22, 2026, President Donald Trump completed the withdrawal of the United States from the World Health Organization (WHO), a specialized agency of the United Nations, a year after he signed Executive Order 14155 on January 20, 2025. As announced by the Department of Health and Human Services, the United States officially exited the organization, ending its 78-year membership and halting all U.S. funding and participation in the WHO's governance and activities. Although the organization hoped for a reconsideration the day after Trump's executive order, the administration continued with the decision. The administration justified the withdrawal by citing concerns about the WHO's handling of global health emergencies, including the COVID-19 pandemic, its resistance to reforms, and its failure to operate independently from inappropriate political influence of other WHO member states. In a joint statement by Secretary of State Marco Rubio and Secretary of Health and Human Services Robert F. Kennedy Jr., they said that the WHO "tarnished and trashed everything that America has done for it" and it "abandoned its core mission and acted repeatedly against the interests of the United States", including the failure to "hand over the American flag that hung in front of it". The United States still owes outstanding dues to the WHO from 2024 to 2025, raising questions about the legality and financial implications of the exit.
== Description == Strobilanthes alternata is a herbaceous plant that reaches approximately 30 cm (12 in) in length. The stems of the plant are prostrate and purplish, especially at the nodes. The leaves, which are covered in fine hairs, are arranged oppositely on the stem with one leaf noticeably larger than its counterpart. The leaf blades are dark green on the top face and are lighter green or purplish on the lower face. Commonly known as the Cemetery plant, Purple waffle plant, or Murikooti, it is referred to in Ayurvedic medicine as Vranaropani, which translates to "wound healer". In Kerala, India, the local name for this herb is Muriyan pacha, a name related to belief in its wound-healing properties. This plant is native to the tropical regions of the globe especially tropical Malaysia and South East Asia. This natural herb grows in plenty across India, China, Indonesia, and Japan
Most naturally occurring fatty acids have an unbranched chain of carbon atoms, with a carboxyl group (–COOH) at one end, and a methyl group (–CH3) at the other end. The position of each carbon atom in the backbone of a fatty acid is usually indicated by counting from 1 at the −COOH end. Carbon number x is often abbreviated C-x (or sometimes Cx), with x = 1, 2, 3, etc. This is the numbering scheme recommended by the IUPAC. Another convention uses letters of the Greek alphabet in sequence, starting with the first carbon after the carboxyl group. Thus carbon α (alpha) is C-2, carbon β (beta) is C-3, and so forth. Although fatty acids can be of diverse lengths, in this second convention the last carbon in the chain is always labelled as ω (omega), which is the last letter in the Greek alphabet. A third numbering convention counts the carbons from that end, using the labels "ω", "ω−1", "ω−2". Alternatively, the label "ω−x" is written "n−x", where the "n" is meant to represent the number of carbons in the chain. In either numbering scheme, the position of a double bond in a fatty acid chain is always specified by giving the label of the carbon closest to the carboxyl end. Thus, in an 18 carbon fatty acid, a double bond between C-12 (or ω−6) and C-13 (or ω−5) is said to be "at" position C-12 or ω−6. The IUPAC naming of the acid, such as "octadec-12-enoic acid" (or the more pronounceable variant "12-octadecanoic acid") is always based on the "C" numbering. The notation Δx,y,... is traditionally used to specify a fatty acid with double bonds at positions x,y,....
==== Collaboration ==== BTS has collaborated with Starbucks to help support the youth in South Korea. Starbucks prepared limited edition merchandise and beverages that have the same shade of purple reminiscent of a starry night, while playing one of BTS songs "Make It Right" in the store. Through this event, Starbucks raised funds to support The Beautiful Foundation.
Cells within the pancreas help to maintain blood glucose levels (homeostasis). The cells that do this are located within the pancreatic islets that are present throughout the pancreas. The following processes take place with blood glucose levels:
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Reverse-phase high-performance liquid chromatography with ultraviolet detection is the usual choice, with results reported as area percent. Complementary methods such as size-exclusion chromatography and mass spectrometry are needed because a single separation cannot resolve every impurity class. Purity figures are therefore method dependent and should always be read alongside the technique used.